2,3,4,9-tetrahydro-1 H -carbazole derivatives as CRTH2...

Details 2,3,4,9-tetrahydro-1 H -carbazole derivatives as CRTH2... 2,3,4,9-tetrahydro-1 H -carbazole derivatives as CRTH2...

2005-12-22

2011-10-18

Qazi, Sabiha (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S290000, C514S307000, C514S411000, C540S479000, C544S372000, C546S110000, C548S441000

Reexamination Certificate

active

08039474

ABSTRACT:
The invention relates to novel tetrahydro-1H-carbazole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds to patients.

REFERENCES:
patent: 4808608 (1989-02-01), Guindon et al.
patent: 1 505 061 (2005-02-01), None
patent: 1 600 440 (2005-11-01), None
patent: 2 388 540 (2003-11-01), None
patent: 2 407 318 (2005-04-01), None
patent: WO 01/79169 (2001-10-01), None
patent: WO 02/094830 (2002-11-01), None
patent: WO-03/051837 (2003-06-01), None
patent: WO-03/062200 (2003-07-01), None
patent: WO 03/066046 (2003-08-01), None
patent: WO 03/066047 (2003-08-01), None
patent: WO 03/097042 (2003-11-01), None
patent: WO 03/097598 (2003-11-01), None
patent: WO 03/101961 (2003-12-01), None
patent: WO 2003/101981 (2003-12-01), None
patent: WO 2004/007451 (2004-01-01), None
patent: WO 2004/039807 (2004-05-01), None
patent: WO 2004/078719 (2004-09-01), None
patent: WO 2004/103970 (2004-12-01), None
patent: WO 2004/106302 (2004-12-01), None
patent: WO 2004/111047 (2004-12-01), None
patent: WO 2005/019171 (2005-03-01), None
patent: WO 2005/040112 (2005-05-01), None
patent: WO 2005/040114 (2005-05-01), None
patent: WO 2005/044260 (2005-05-01), None
patent: WO 2005/054232 (2005-06-01), None
patent: WO 2005/056527 (2005-06-01), None
patent: WO 2005/073234 (2005-08-01), None
patent: WO 2005/094816 (2005-10-01), None
patent: WO 2005/095397 (2005-10-01), None
patent: WO 2006/021418 (2006-03-01), None
patent: WO 2008/017989 (2008-02-01), None
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
Sugimoto, H. et al.; “An Orally Bioavailable Small Molecule Antagonist of CRTH2, Ramatroban (BAY u3405), Inhibits Prostaglandin D2-Induced Eosinophil Migration in Vitro”; The Journal of Pharacology and Experimental Therapeutics, 2003, vol. 305, No. 1, pp. 347-352.
Berge, Stephen M., et al.; “Pharmaceutical Salts”; Journal of Pharmaceutical Sciences, Jan. 1977, vol. 66, No. 1, pp. 1-19.
Bundgaard, H.; “Design of Prodrugs”; 1985 Elsevier Amsterdam, pp. 7-9, 21-24.
Silverman R.B.; The Organic Chemistry of Drug Design and Drug Action; pp. 352-401, Academic Press, San Diego, CA (1992).
Higuchi, T. et al.; “Pro-drugs as Novel Drug Delivery Systems”; A.C.S. Symposium Series, American Chemical Society, 1975, vol. 14, pp. 154-183.
Sawyer, N. et al.; “Molecular pharmacology of the human prostaglandin D2receptor, CRTH2”; British Journal of Pharmacology (2002), vol. 137, pp. 1163-1172.
Larock Richard C.; “Comprehensive Organic Transformations”; Wiley-VCH Publishers, 1999.
Greene, Theodora W., et al.; “Protective Groups in Organic Synthesis”; Wiley-Interscience (1999).
Block, Michael H. et al.; “Discovery and Optimization of a Series of Carbazole Ureas as NPY5 Antagonists for the Treatment of Obesity”; Journal of Medicinal Chemistry, 2002, vol. 45, No. 16, pp. 3509-3523.
Wustrow, David et al.; Aminopyrimidines with High Affinity for Both Serotonin and Dopamine Receptors'; Journal of Medicinal Chemistry, 1998, vol. 41, No. 5, pp. 760-771.
Rubin, Martin et al.; “1-Methyl-3-ethyl-4-(p—hydroxyphenyl)-Δ3-cyclohexenylethylcarbinol, and “Open-Model” of Estradiol”; J. Amer. Chem. Soc. 1946, vol. 68, pp. 338-340.
Chapman, N.B. et al.; “The Preparation of 4-Substituted 1-Methoxycarbonylbicyclo[2.2.2]octanes, Substituted 1-Phenylbicyclo[2.2.2]octanes, 4-Substituted 1-p—Nitrophenylbicyclo[2.2.2]octanes, and 1,4-Disubstituted Bicyclo[2.2.2]octanes”; The Journal of Organic Chemistry, vol. 35, No. 4, Apr. 1970, pp. 917-923.
Bruson, Herman A. et al.; “The Chemistry of Acrylonitrile. II. Reactions with Ketones”; J. Amer. Chem. Soc. 1942, vol. 64, pp. 2850-2858.
Kotake, Y. et al.; “Novel 6-5 Fused Ring Heterocycle Antifolates with Potent Antitumor Activity: Bridge Modifications and Heterocyclic Benzoyl Isosters of 2,4-Diamino-6,7-dihydro-5H—cyclopenta[d]pyrimidine Antifolate”; Chem. Pharm. Bull, May 1995, vol. 43, No. 5, pp. 829-841.
Arcari, M. et al; “Synthesis and Pharmacological Evaluation of 2,3-Dialkylindoles, “In Vitro” Inhibitors of Thrombin-Induced Platelet Aggregation”; II Farmaco, vol. 47, No. 4, pp. 405-425, 1992.
Beller, M. et al.; “Base-Catalyzed Synthesis ofN-(2-Arylethyl)anilines and Base-Promoted Domino Synthesis of 2,3-Dihydroindoles”; Angew. Chem. Int. Ed., 1998, vol. 37, No. 24, pp. 3389-3391.
Kwong, Fuk Yee et al; “Copper-Catalyzed Coupling of Alkylamines and Aryl Iodides: An Efficient System Even in an Air Atmosphere”; Organic Letters, 2002, vol. 4, No. 4, pp. 581-584.
Lewin, G. et al; “One-Pot Access to 2,3-Disbustituted 1,2,3,4-Tetrahydroquinolines by Reductive Amination of Aldehydes with Sodium Cyanoborohydride”; Heterocycles, vol. 48, No. 1, 1998, pp. 171-174.
Monro, A.M. et al.; “Some Analogs of Imipramine”; J. Med. Chem., 1963, vol. 6, pp. 255-261.
Warawa, Edward J. et al.; “Behavioral Approach to Nondyskinetic Dopamine Antagonists: Identification of Seroquel”; J. Med. Chem., 2001, vol. 44, pp. 372-389.
Werner, L.H. et al.; “Derivatives of Morphanthridine”; J. Med. Chem., 1965, vol. 8, pp. 74-80.
Margolis, Brandon J. et al.; “An Efficient Assembly of Heterobenzazepine Ring Systems Utilizing and Intramolecular Palladium-Catalyzed Cycloamination”; J. Org. Chem., 2003, vol. 68, pp. 644-647.
Bryant, William S. et al.; “A Study of the Complexation of Bis(m-Phenylene) Crown Ethers and Secondary Ammonium Ions”; J. Org. Chem., 1998, vol. 63, pp. 7634-7639.
Albright, J. Donald et al.; “Potential Antiatherosclerotic Agents. 2.1(Aralkylamino)-and (Alkylamino)benzoic Acid Analogues of Cetaben”; J. Med. Chem., 1983, vol. 26, pp. 1378-1393.
Ishizuka et al., Cardiovascular Drug Reviews, vol. 22, No. 2, pp. 71-90 (2004).
Robarge et al., Bioorganic & Medicinal Chemistry Letters, vol. 15, pp. 1749-1753 (2005).
Ulven et al., Journal of Medicinal Chemistry, vol. 48, No. 4, pp. 897-900 (2005).

Affiliated with

Also associated with

Rating

2,3,4,9-tetrahydro-1 H -carbazole derivatives as CRTH2... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2,3,4,9-tetrahydro-1 H -carbazole derivatives as CRTH2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,3,4,9-tetrahydro-1 H -carbazole derivatives as CRTH2... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4287601